Projects

Project Date
30 Sep 2023 - 30 Jun 2028

Funding
National Institute on Drug Abuse R01 grant - R01DA057943

Researchers

  • Thuy Nguyen (Contact Principal Investigator)
  • Mark Bicket (Multiple Princial Investigator)

Project Summary
Medications for opioid use disorder (MOUD)–buprenorphine, methadone, and naltrexone–decrease illicit opioid use, increase retention in treatment, and save lives. However, for patients taking MOUD, and buprenorphine in particular, the treatment of acute pain after surgery is challenging. Buprenorphine is a partial opioid agonist that acts as a competitive antagonist for traditional opioids. Due to this fact, perioperative guidelines have historically advocated that patients temporarily discontinue buprenorphine before surgery. However, the national conversation has recently shifted with guidelines recommending that buprenorphine, and to a lesser extent methadone, be continued in the perioperative setting. The evidence supporting this change has relied on small samples, non-surgical cohorts, and studies failing to examine relevant outcomes for pain and opioid use disorder. In this proposal, we will use several state-of-the-art national databases to achieve a better understanding of perioperative management of MOUD and the consequences of therapy retention on opioid overdose risk. 

Publications

  • Bicket MC, Chua KP, Lagisetty P, Li Y, Waljee J, Brummett C, Nguyen TD. Prevalence of Surgery Among Individuals in the United States. Annals of Surgery 5(2):p e421, June 2024.DOI: 10.1097/AS9.0000000000000421.
    https://journals.lww.com/aosopen/pages/default.aspx 
  • Chua KP, Bicket MC, Bohnert ASB, Conti RM, Lagisetty P, Nguyen TD. Buprenorphine Dispensing after Elimination of the Waiver Requirement. N Engl J Med. 2024;390(16):1530-1532. doi:10.1056/NEJMc2312906.
    https://www.nejm.org/doi/full/10.1056/NEJMc2312906 

In the News

Project Date
30 Sep 2022 - Present

Researchers

  • Thuy Nguyen 
  • Kao-Ping Chua 
  • Pooja Lagisetty
  • Amy Bohnert

Project Summary
Despite a substantial rise in U.S. opioid overdose deaths in recent years, buprenorphine, a medication for opioid use disorder (OUD) that substantially decreases fatal overdose risk, remains widely underused, even after emergency department visits for opioid overdose. Moreover, little is known about buprenorphine treatment among the 38% of low-income adults with OUD covered by Medicaid, a disproportionate share of whom are people of color. To address this knowledge gap, the team will analyze racial and ethnic disparities in the receipt of buprenorphine among Medicaid enrollees to inform targeted interventions focused on improving equity of buprenorphine treatment.

In the News

Project Date
30 Sep 2022 - 31 Jul 2026

Funding
National Institute on Drug Abuse R01 grant - R01DA056438

Researchers

  • Kao-Ping Chua (Contact Principal Investigator)
  • Thuy Nguyen (Multiple Princial Investigator)

Project Summary
In 2020, a record 71,000 opioid overdose deaths occurred in the U.S, highlighting the importance of mitigating insurance-related barriers to accessing medications for opioid use disorder (MOUD). In this proposal, we will provide actionable, policy-relevant information on the effect of cost-sharing for MOUD in privately insured patients and on the effect of removing prior authorization requirements for MOUD in Medicaid patients. Results will inform and spur efforts to optimize insurance benefit design for MOUD in private and Medicaid plans, potentially leading to the removal of insurance-related barriers that may be contributing to rising opioid-related morbidity and mortality.

Publications

  • Chua KP, Bicket MC, Bohnert ASB, Conti RM, Lagisetty P, Nguyen TD. Buprenorphine Dispensing after Elimination of the Waiver Requirement. N Engl J Med. 2024;390(16):1530-1532. doi:10.1056/NEJMc2312906.
    https://www.nejm.org/doi/full/10.1056/NEJMc2312906  
  • Chua KP, Nguyen TD, Zhang J, Conti RM, Lagisetty P, Bohnert AS. Trends in Buprenorphine Initiation and Retention in the United States, 2016-2022. JAMA. 2023;329(16):1402-1404. doi:10.1001/jama.2023.1207
    https://pubmed.ncbi.nlm.nih.gov/37097363/
  • Chua KP, Nguyen TD, Waljee JF, Nalliah RP, Brummett CM. Association Between State Opioid Prescribing Limits and Duration of Opioid Prescriptions From Dentists. JAMA Netw Open. 2023;6(1):e2250409. Published 2023 Jan 3. doi:10.1001/jamanetworkopen.2022.50409
    https://pubmed.ncbi.nlm.nih.gov/36630136/
  • Andraka-Christou B, Simon KI, Bradford WD, Nguyen T. Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017-21. Health Aff (Millwood). 2023;42(5):658-664. doi:10.1377/hlthaff.2022.01513
    https://pubmed.ncbi.nlm.nih.gov/37126752/ 

In the News

Project Date
01 Jan 2021 - Present

Researchers

  • Thuy Nguyen
  • Christopher Whaley
  • Kosali Simon
  • Jonathan Cantor


Project Summary
The COVID-19 pandemic has caused a variety of disruptions to the health care workforce. Although publications on select workforce sectors chronicle patterns in employment through the early pandemic, there is a lack of national studies on the broad health care workforce using more recent data in this period of rapid change. This limits the ability of health care organizations and policy makers to ensure that patient needs are met. This project aims to address this knowledge gap, providing data driven insights into health care employment using large national databases.

Publications

In the News

Project Date
1 Sep 2019 - present

Researchers

  • Thuy Nguyen
  • Kosali Simon
  • David Bradford
  • Basia Andraka-Christou

Project Summary
In 2020, a record 71,000 opioid overdose deaths occurred in the U.S, highlighting the importance of mitigating insurance-related barriers to accessing medications for opioid use disorder (MOUD). In this proposal, we will provide actionable, policy-relevant information on the effect of cost-sharing for MOUD in privately insured patients and on the effect of removing prior authorization requirements for MOUD in Medicaid patients. Results will inform and spur efforts to optimize insurance benefit design for MOUD in private and Medicaid plans, potentially leading to the removal of insurance-related barriers that may be contributing to rising opioid-related morbidity and mortality.

Publications

  • Nguyen TD, Bradford WD, Simon KI. Pharmaceutical payments to physicians may increase prescribing for opioids. Addiction. 2019;114(6):1051-1059. doi:10.1111/add.14509
    https://pubmed.ncbi.nlm.nih.gov/30667135/
  • Nguyen T, Andraka-Christou B, Simon K, Bradford WD. Comparison of Rural vs Urban Direct-to-Physician Commercial Promotion of Medications for Treating Opioid Use Disorder. JAMA Netw Open. 2019;2(12):e1916520. Published 2019 Dec 2. doi:10.1001/jamanetworkopen.2019.16520
    https://pubmed.ncbi.nlm.nih.gov/31790568/
  • Nguyen T, Andraka-Christou B, Simon K, Bradford WD. Provider-directed marketing may increase prescribing of medications for opioid use disorder. J Subst Abuse Treat. 2019;104:104-115. doi:10.1016/j.jsat.2019.06.014
    https://pubmed.ncbi.nlm.nih.gov/31370974/
  • Scrivner O, Nguyen T, Simon K, Middaugh E, Taska B, Börner K. Job postings in the substance use disorder treatment related sector during the first five years of Medicaid expansion. PLoS One. 2020;15(1):e0228394. Published 2020 Jan 30. doi:10.1371/journal.pone.0228394
    https://pubmed.ncbi.nlm.nih.gov/31999764/
  • Andraka-Christou B, Nguyen T, Bradford DW, Simon K. Assessing the impact of drug courts on provider-directed marketing efforts by manufactures of medications for the treatment of opioid use disorder. J Subst Abuse Treat. 2020;110:49-58. doi:10.1016/j.jsat.2019.12.004
    https://pubmed.ncbi.nlm.nih.gov/31952628/
  • Nguyen TD, Gupta S, Ziedan E, et al. Assessment of Filled Buprenorphine Prescriptions for Opioid Use Disorder During the Coronavirus Disease 2019 Pandemic. JAMA Intern Med. 2021;181(4):562-565. doi:10.1001/jamainternmed.2020.7497
    https://pubmed.ncbi.nlm.nih.gov/33346795/
  • Sacks DW, Hollingsworth A, Nguyen T, Simon K. Can policy affect initiation of addictive substance use? Evidence from opioid prescribing. J Health Econ. 2021;76:102397. doi:10.1016/j.jhealeco.2020.102397
    https://pubmed.ncbi.nlm.nih.gov/33383263/
  • Nguyen T, Muench U, Andraka-Christou B, Simon K, Bradford WD, Spetz J. The Association Between Scope of Practice Regulations and Nurse Practitioner Prescribing of Buprenorphine After the 2016 Opioid Bill. Med Care Res Rev. 2022;79(2):290-298. doi:10.1177/10775587211004311
    https://pubmed.ncbi.nlm.nih.gov/33792414/
  • Nguyen T, Cantor J, Andraka-Christou B, Bradford WD, Simon K. Where did the specialty behavioral health workforce grow between 2011 and 2019? Evidence from census data. J Subst Abuse Treat. 2021;130:108482. doi:10.1016/j.jsat.2021.108482
    https://pubmed.ncbi.nlm.nih.gov/34118714/
  • Nguyen T, Andraka-Christou B, Bradford WD, Simon K. Opting into the Public List of DATA-Waivered Practitioners: Variations by Specialty, Treatment Capacity, and Practitioner Characteristics. J Addict Med. 2022;16(3):e197-e202. doi:10.1097/ADM.0000000000000911
    https://pubmed.ncbi.nlm.nih.gov/34669615/ 

In the News